Abeona Therapeutics reported an 18% sequential increase in Q3 2026 net revenue for ZEVASKYN, reaching $13.5 million, with 15 patient treatments completed since launch. The company expanded its qualified treatment center network to eight sites and secured New Technology Add-On Payment status for ZEVASKYN, improving Medicare reimbursement. Abeona also acquired the Phase 3-ready ABO-801 for eosinophilic esophagitis and raised $30 million through private placement financing to support pipeline development and commercialization efforts. The company posted a net loss of $4.8 million for the quarter but maintains a strong cash position of $134.9 million as of September 30, 2026.
Following Abeona Therapeutics' Q3 2026 update on ZEVASKYN and pipeline progress, its stock price on Pluang is currently USD 3.99, down 4.32% for the day as of Nov 09, 2026 18:41 WIB. The company holds a market cap of $238.46 million, trading near its 52-week low of $3.91. Typical investors hold the stock for about 28 days on the platform.
